How I treat chemorefractory metastatic colorectal cancer

Clin Adv Hematol Oncol. 2018 May;16(5):340-345.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology
  • Drug Combinations
  • Drug Resistance, Neoplasm
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Lapatinib
  • Lymphatic Metastasis
  • Neoplasm Staging
  • Nivolumab
  • Phenylurea Compounds / therapeutic use
  • Prognosis
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics*
  • Proto-Oncogene Proteins B-raf / metabolism
  • Pyridines / therapeutic use
  • Pyrrolidines
  • Quinazolines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Thymine
  • Trastuzumab / therapeutic use
  • Trifluridine / therapeutic use
  • Uracil / analogs & derivatives
  • Uracil / therapeutic use
  • Vascular Endothelial Growth Factor Receptor-1 / antagonists & inhibitors
  • Vascular Endothelial Growth Factor Receptor-1 / genetics*
  • Vascular Endothelial Growth Factor Receptor-1 / metabolism

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Drug Combinations
  • Phenylurea Compounds
  • Pyridines
  • Pyrrolidines
  • Quinazolines
  • trifluridine tipiracil drug combination
  • Lapatinib
  • regorafenib
  • Nivolumab
  • Uracil
  • pembrolizumab
  • Vascular Endothelial Growth Factor Receptor-1
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Trastuzumab
  • Thymine
  • Trifluridine